We are live on ! Find out more
DMAQR

Deep Medicine Acquisition Corp. Rights
DMAQR

Delisted

DMAQR was delisted on the 31st of January, 2024.

30 hedge funds and large institutions have $388K invested in Deep Medicine Acquisition Corp. Rights in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 3130 (-1)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

65% less capital invested

Capital invested by funds: $1.09M → $388K (-$706K)

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
5
Closed
3
Calls
$333K
Puts
Net Calls
+$333K
Net Calls Change

DMAQR Hedge Fund Activity: Q3 2022 in Review

30 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q3 2022, worth a combined $388K — down 65% from $1.09M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of DMAQR and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.

The largest buyer was Cowen and Company, adding an estimated $49.3K. The largest seller was HGC Investment Management, exiting entirely with an estimated $54K sold.

  • 30 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q3 2022, down from 31 in Q2 2022.
  • Funds reported $388K of Deep Medicine Acquisition Corp. Rights stock for Q3 2022, down 65% quarter-over-quarter.
  • 2 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q3 2022 and 3 closed out, a net change of -1 holder.
  • The largest Deep Medicine Acquisition Corp. Rights buyer in Q3 2022 was Cowen and Company, an estimated $49.3K added.
  • The largest Deep Medicine Acquisition Corp. Rights seller in Q3 2022 was HGC Investment Management, an estimated $54K sold.

Based on aggregated 13F filings for Q3 2022.